Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Trials in LMIC and HIC – are the standards applicable globally ?

Choosing Wisely 2022 Mumbai

17 - 18 Sep 2022

Published: 19 Sep 2022

Views: 3034

Rating:

Save

Dr Amol Patel - INHS Asvini, Mumbai, India

Dr Amol Patel speaks to ecancer about the trials in low-middle-income countries versus high-income countries and how the standards are applied globally.

He discusses how LMIC’s standards are different in comparison to HICs.

He explores the benefits of exchanging results of trials with other healthcare professionals.

Related Videos

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

ASCO's efforts to improve global cancer care through the years

Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru

ASCO's efforts to improve global cancer care through the years ( Dr Carlos Santiago Vallejos Sologuren - Oncosalud, Lima, Peru )

African oncologists interaction with pharmaceutical industry

Prof Nazik Hammad - Queen's University, Kingston, Canada

African oncologists interaction with pharmaceutical industry ( Prof Nazik Hammad - Queen's University, Kingston, Canada )

The role of the workforce in implementing Choosing Wisely in cancer care

Prof Nazik Hammad - Queen's University, Kingston, Canada

The role of the workforce in implementing Choosing Wisely in cancer care ( Prof Nazik Hammad - Queen's University, Kingston, Canada )

Choosing Wisely to mitigate financial toxicity in cancer care in Africa

Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Redefining cancer research priorities in the emerging context of the COVID-19...

Prof Richard Sullivan - King's College London, London, UK

Redefining cancer research priorities in the emerging context of the COVID-19 pandemic ( Prof Richard Sullivan - King's College London, London, UK )

Interpreting statistics in clinical trials

Dr Sudeep Gupta - Tata Medical Centre, Mumbai, India

Interpreting statistics in clinical trials ( Dr Sudeep Gupta - Tata Medical Centre, Mumbai, India )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Global obstacles to lung cancer screening: Report

Professor Rudolf Huber - The Hospital of the University of Munich, Munich...

Global obstacles to lung cancer screening: Report ( Professor Rudolf Huber - The Hospital of the University of Munich, Munich, Germany )

More from ecancer